We are delighted to announce that Kurt Herpel, CEO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking […]
Category: News
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to […]
Delta4 At BIO-Europe
Delta4 Will Attend BIO-Europe 2023 Delta4 is thrilled to announce that our CEO, Kurt Herpel, and CSO, Klaus Kratochwill, will […]
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the […]
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the […]
Delta4’s Innovation Shines: OntoloViz Article Published in Bioinformatics Advances Journal
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or […]
Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI […]
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In […]
Delta4 expands Team and tackles new indications
A Welcome to Our Newest Member Following our Financing in March 2021 and our move into new premises in July […]
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city […]